



Kisunla in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

NEUROLOGY · EARLY ALZHEIMER'S DISEASE

The clinical situation

Kisunla (donanemab-azbt) is an IV anti-amyloid-plaque monoclonal antibody FDA-approved for early Alzheimer's disease (MCI-AD or mild AD dementia) with confirmed amyloid pathology. Manufactured by Eli Lilly. Dosing is every 4 weeks with a unique time-limited paradigm: discontinuation can be considered when amyloid clearance is imaged. Pre-treatment requires amyloid confirmation (PET or CSF), baseline MRI, ApoE genotyping, and ARIA (amyloid-related imaging abnormalities) monitoring per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist or geriatrician documents MCI/mild-AD stage, cognitive assessment, and Kisunla rationale.
- 2 Amyloid & MRI workup.** Amyloid PET or CSF confirmation, baseline MRI, ApoE genotyping, and ARIA-risk counselling completed per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, infusion-facility plan, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first infusion.** Infusion facility administers first dose with ongoing ARIA surveillance MRI at labelled intervals and amyloid re-imaging at the discontinuation decision point.

Indicative economics

Reference US cash-pay range: USD 32,000–36,000 per year of Kisunla (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Eli Lilly authorised distribution.

Documentation. Physician kit tailored to SFDA review, with anti-amyloid ARIA-monitoring and discontinuation-paradigm annex.

Logistics. Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through infusion cycles. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Kisunla × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/kisunla-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team